» Articles » PMID: 20705094

Sf9 Cells: a Versatile Model System to Investigate the Pharmacological Properties of G Protein-coupled Receptors

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2010 Aug 14
PMID 20705094
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The Sf9 cell/baculovirus expression system is widely used for high-level protein expression, often with the purpose of purification. However, proteins may also be functionally expressed in the defined Sf9 cell environment. According to the literature, the pharmacology of G-protein-coupled receptors (GPCRs) functionally reconstituted in Sf9 cells is similar to the receptor properties in mammalian cells. Sf9 cells express both recombinant GPCRs and G-proteins at much higher levels than mammalian cells. Sf9 cells can be grown in suspension culture, providing an inexpensive way of obtaining large protein amounts. Co-infection with various baculoviruses allows free combination of GPCRs with different G-proteins. The absence of constitutively active receptors in Sf9 cells provides an excellent signal-to background ratio in functional assays, allowing the detection of agonist-independent receptor activity and of small ligand-induced signals including partial agonistic and inverse agonistic effects. Insect cell Gα(i)-like proteins mostly do not couple productively to mammalian GPCRs. Thus, unlike in mammalian cells, Sf9 cells do not require pertussis toxin treatment to obtain a Gα(i)-free environment. Co-expression of GPCRs with Gα(i1), Gα(i2), Gα(i3) or Gα(o) in Sf9 cells allows the generation of a selectivity profile for these Gα(i/o)-isoforms. Additionally, GPCR-G-protein combinations can be compared with defined 1:1 stoichiometry by expressing GPCR-Gα fusion proteins. Sf9 cells can also be employed for ligand screening in medicinal chemistry programs, using radioligand binding assays or functional assays, like the steady-state GTPase- or [(35)S]GTPγS binding assay. This review shows that Sf9 cells are a versatile model system to investigate the pharmacological properties of GPCRs.

Citing Articles

Highly selective split intein method for efficient separation and purification of recombinant therapeutic proteins from mammalian cell culture fluid.

Prabhala S, Marshall B, Galiardi J, Fan Y, Creamer E, Wood D J Chromatogr A. 2024; 1736:465430.

PMID: 39405639 PMC: 11533640. DOI: 10.1016/j.chroma.2024.465430.


Structural Insights into Partial Activation of the Prototypic G Protein-Coupled Adenosine A Receptor.

Claff T, Mahardhika A, Vaassen V, Schlegel J, Vielmuth C, Weisse R ACS Pharmacol Transl Sci. 2024; 7(5):1415-1425.

PMID: 38751633 PMC: 11091970. DOI: 10.1021/acsptsci.4c00051.


Agonist-selective activation of individual G-proteins by muscarinic receptors.

Nelic D, Chetverikov N, Hochmalova M, Diaz C, Dolezal V, Boulos J Sci Rep. 2024; 14(1):9652.

PMID: 38671143 PMC: 11053168. DOI: 10.1038/s41598-024-60259-4.


Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.

Demirden S, Kimiz-Gebologlu I, Oncel S ACS Omega. 2024; 9(15):16904-16926.

PMID: 38645343 PMC: 11025085. DOI: 10.1021/acsomega.3c10484.


Illuminating Neuropeptide Y Y Receptor Binding: Fluorescent Cyclic Peptides with Subnanomolar Binding Affinity as Novel Molecular Tools.

Gleixner J, Kopanchuk S, Gratz L, Tahk M, Laasfeld T, Veiksina S ACS Pharmacol Transl Sci. 2024; 7(4):1142-1168.

PMID: 38633582 PMC: 11019746. DOI: 10.1021/acsptsci.4c00013.